A Phase II, Randomised, Factorial, Double-Blind Study to Investigate the Management of AZD2171-Induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients With Advanced Solid Tumours.

Trial Profile

A Phase II, Randomised, Factorial, Double-Blind Study to Investigate the Management of AZD2171-Induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients With Advanced Solid Tumours.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2012

At a glance

  • Drugs Cediranib (Primary) ; Calcium channel antagonists
  • Indications Hypertension; Solid tumours
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 Aug 2011 Actual end date Apr 2011 added as reported by ClinicalTrials.gov.
    • 24 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jun 2011 Planned end date changed from 1 Jun 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top